AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Derivative Acquisition Under Employee Benefit Plan

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Aradhana Sarin	CFO & Executive Director Show All	Sale	-15.0K	—	—	—	88.9 - 88.9	-1.3M	12 Nov 2025	12 Nov 2025 - 12 Nov 2025
Pascal Claude Roland Soriot	CEO & Executive Director Show All	Other Acquisition (Other Acquisition)	136.5K	0.008804%	35.3%	522.9K	—	—	10 Nov 2025	07 Nov 2025 - 07 Nov 2025
Pascal Claude Roland Soriot	CEO & Executive Director Show All	Other Disposition (Other Disposition)	-136.5K	-0.008804%	-100.0%	—	—	—	10 Nov 2025	07 Nov 2025 - 07 Nov 2025
Pascal Claude Roland Soriot	CEO & Executive Director Show All	Other Disposition (Other Disposition)	-136.5K	-0.008804%	-26.1%	386.4K	—	—	10 Nov 2025	07 Nov 2025 - 07 Nov 2025
Karen E. Knudsen	Non-Executive Director Show All	Other Acquisition (Other Acquisition)	5.0	—	0.6%	705.0	81.0 - 81.0	368.0	25 Sep 2025	09 Sep 2025 - 09 Sep 2025
Aradhana Sarin
Aradhana Sarin
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Aradhana Sarin
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Aradhana Sarin
Aradhana Sarin
Pascal Claude Roland Soriot
Michel Roger Demare
Pascal Claude Roland Soriot
Philip Arthur John Broadley
Michel Roger Demare
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Pascal Claude Roland Soriot
Aradhana Sarin
Pascal Claude Roland Soriot